Literature DB >> 31032103

Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.

Eke Ransome1, Li Tong1, Jairo Espinosa2, Jesse Chou3, Vishal Somnay3, Gitonga Munene2,3.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (IHC) is a malignancy with an increasing incidence. Surgery is the only treatment modality associated with long term survival. The objective of this study is to utilize a nationwide representative database to quantify the trends in incidence, and surgery for IHC in the United States from 2004-2014, as well as identify any disparities in the receipt of surgery.
METHODS: All patients admitted with a diagnosis of IHC between 2005 and 2014 were identified from the Nationwide Inpatient Sample (NIS) database. Trends in the number of IHC admissions and surgery procedures as well as outcomes were examined, and a multivariate analysis was used to determine the effects of demographic and clinical co-variables on resection rates.
RESULTS: An estimated total of 104,045 IHC related admissions occurred between 2005 and 2014. The hospitalization rate for IHC increased by nearly 2-fold in 2014 [38.9 per 100,000 (95% CI, 35.7-42.2)] from 18.1 per 100,000 (95% CI, 15.8-20.3) in 2005. Liver resections increased 248% (P<0.01) with an increasing majority being performed at teaching hospitals and 56% being minor resections. There was an increase in estimated hospital charges from $87,124 to $148,613 (P<0.001) and decrease in LOS from 12 days to 10 days (P<0.01). Inpatient mortality for IHC decreased significantly from 11% to 8.4% (P=0.004), from year 2005 to 2014 respectively. Age >80 years (OR =0.45; 95% CI, 0.33-0.60), Black race (OR =0.50; 95% CI, 0.39-063), Hispanic race (OR =0.59; 95% CI, 0.45-0.79), Medicaid insurance (OR =0.58; 95% CI, 0.42-0.79) and Elixhauser comorbidity score >3 (OR =0.58; 95% CI, 0.47-0.73) were associated with decreased rates of resection.
CONCLUSIONS: Overall hospitalization and volume of surgery for IHC has increased dramatically over the past decade. There has been an increase in cost, decrease in LOS and inpatient mortality during the period. Socioeconomic and racial disparities were observed in the receipt of surgery for IHC. Additional work is needed to understand the complex interplay between socioeconomic status and race in in the treatment of IHC.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; disparity; surgery

Year:  2019        PMID: 31032103      PMCID: PMC6465498          DOI: 10.21037/jgo.2018.12.07

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  29 in total

1.  National trends in the use and outcomes of hepatic resection.

Authors:  Justin B Dimick; Reid M Wainess; John A Cowan; Gilbert R Upchurch; James A Knol; Lisa M Colletti
Journal:  J Am Coll Surg       Date:  2004-07       Impact factor: 6.113

Review 2.  Cholangiocarcinoma.

Authors:  Tushar Patel
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-01

Review 3.  Cholangiocarcinoma.

Authors:  Shahid A Khan; Howard C Thomas; Brian R Davidson; Simon D Taylor-Robinson
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

4.  Surgical management of intrahepatic cholangiocarcinoma--a population-based study.

Authors:  Jensen C C Tan; Natalie G Coburn; Nancy N Baxter; Alex Kiss; Calvin H L Law
Journal:  Ann Surg Oncol       Date:  2007-11-07       Impact factor: 5.344

Review 5.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

6.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

7.  National failure to operate on early stage pancreatic cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

8.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

9.  Worldwide trends in mortality from biliary tract malignancies.

Authors:  Tushar Patel
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

10.  Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.

Authors:  J West; H Wood; R F A Logan; M Quinn; G P Aithal
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

View more
  7 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.

Authors:  Yi-Te Lee; Amit G Singal; Marie Lauzon; Vatche G Agopian; Michael Luu; Mazen Noureddin; Tsuyoshi Todo; Irene K Kim; Marc L Friedman; Kambiz Kosari; Nicholas N Nissen; Lewis R Roberts; Julie K Heimbach; Gregory J Gores; Ju Dong Yang
Journal:  Cancer       Date:  2022-08-23       Impact factor: 6.921

3.  Updates in Cholangiocarcinoma.

Authors:  Kristen O'Hagan
Journal:  J Adv Pract Oncol       Date:  2022-05-23

4.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

Review 5.  Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.

Authors:  Giovanni Brandi; Kurt Straif; Daniele Mandrioli; Stefania Curti; Stefano Mattioli; Simona Tavolari
Journal:  Ann Glob Health       Date:  2022-06-13       Impact factor: 3.640

6.  Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis.

Authors:  Christina X Chamberlain; Elizabeth Faust; Debbie Goldschmidt; Nathan Webster; Audra N Boscoe; Dendy Macaulay; Mary Linton Peters
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery.

Authors:  Lauren F Huang; Augustine Hong; Gino Cioffi; Asrar Alahmadi; Tin-Yun Tang; Lee M Ocuin; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Monica Webb Hooper; Jill Barnholtz-Sloan; Richard T Lee
Journal:  Front Oncol       Date:  2022-02-22       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.